BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ruthirakuhan M, Herrmann N, Andreazza AC, Verhoeff NPL, Gallagher D, Black SE, Kiss A, Lanctôt KL. Agitation, Oxidative Stress, and Cytokines in Alzheimer Disease: Biomarker Analyses From a Clinical Trial With Nabilone for Agitation. J Geriatr Psychiatry Neurol 2020;33:175-84. [DOI: 10.1177/0891988719874118] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Liu H, Salem Y, Aggarwal S. Effects of Tai Chi on biomarkers and their implication to neurorehabilitation – a systemic review. European Journal of Integrative Medicine 2022;50:101391. [DOI: 10.1016/j.eujim.2021.101391] [Reference Citation Analysis]
2 Ortiz YT, Mcmahon LR, Wilkerson JL. Medicinal Cannabis and Central Nervous System Disorders. Front Pharmacol 2022;13:881810. [DOI: 10.3389/fphar.2022.881810] [Reference Citation Analysis]
3 Deng M, Chen H, Long J, Song J, Xie L, Li X. Calycosin: a Review of its Pharmacological Effects and Application Prospects. Expert Rev Anti Infect Ther 2021;19:911-25. [PMID: 33346681 DOI: 10.1080/14787210.2021.1863145] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bosnjak Kuharic D, Markovic D, Brkovic T, Jeric Kegalj M, Rubic Z, Vuica Vukasovic A, Jeroncic A, Puljak L. Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev 2021;9:CD012820. [PMID: 34532852 DOI: 10.1002/14651858.CD012820.pub2] [Reference Citation Analysis]
5 Wilkerson JL, Bilbrey JA, Felix JS, Makriyannis A, McMahon LR. Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline? Pharmacol Biochem Behav 2021;206:173192. [PMID: 33932409 DOI: 10.1016/j.pbb.2021.173192] [Reference Citation Analysis]
6 Cummings J. The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases. Am J Geriatr Psychiatry 2021;29:375-83. [PMID: 32819825 DOI: 10.1016/j.jagp.2020.07.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Goveas JS. Commentary on "Cannabinoids for Agitation in Alzheimer's Disease". Am J Geriatr Psychiatry 2021;29:1264-6. [PMID: 33839012 DOI: 10.1016/j.jagp.2021.03.004] [Reference Citation Analysis]
8 Bateman DR, Gill S, Hu S, Foster ED, Ruthirakuhan MT, Sellek AF, Mortby ME, Matušková V, Ng KP, Tarawneh RM, Freund-Levi Y, Kumar S, Gauthier S, Rosenberg PB, Ferreira de Oliveira F, Devanand DP, Ballard C, Ismail Z; International Society to Advance Alzheimer's Research and Treatment (ISTAART), Neuropsychiatric Syndromes Professional Interest Area (NPS‐PIA). Agitation and impulsivity in mid and late life as possible risk markers for incident dementia. Alzheimers Dement (N Y) 2020;6:e12016. [PMID: 32995467 DOI: 10.1002/trc2.12016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
9 Gouveia FV, Ibrahim GM. Habenula as a Neural Substrate for Aggressive Behavior. Front Psychiatry 2022;13:817302. [DOI: 10.3389/fpsyt.2022.817302] [Reference Citation Analysis]
10 Höller I, Forkmann T. Brief Self-Report Measure of Agitation: A Psychometric Investigation in a German Sample. J Pers Assess 2021;:1-24. [PMID: 33970724 DOI: 10.1080/00223891.2021.1912057] [Reference Citation Analysis]
11 Spanagel R, Bilbao A. Approved cannabinoids for medical purposes - Comparative systematic review and meta-analysis for sleep and appetite. Neuropharmacology 2021;196:108680. [PMID: 34181977 DOI: 10.1016/j.neuropharm.2021.108680] [Reference Citation Analysis]
12 Padureanu R, Albu CV, Mititelu RR, Bacanoiu MV, Docea AO, Calina D, Padureanu V, Olaru G, Sandu RE, Malin RD, Buga AM. Oxidative Stress and Inflammation Interdependence in Multiple Sclerosis. J Clin Med 2019;8:E1815. [PMID: 31683787 DOI: 10.3390/jcm8111815] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
13 Tumati S, Herrmann N, Marotta G, Li A, Lanctôt KL. Blood-based biomarkers of agitation in Alzheimer's disease: Advances and future prospects. Neurochem Int 2022;152:105250. [PMID: 34864088 DOI: 10.1016/j.neuint.2021.105250] [Reference Citation Analysis]